Cargando…

Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination

BACKGROUND: An AS03-adjuvanted H5N1 influenza vaccine elicited broad and persistent immune responses with an acceptable safety profile up to 6 months following the first vaccination in children aged 3–9 years. METHODS: In this follow-up of the Phase II study, we report immunogenicity persistence and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Díez-Domingo, Javier, Baldó, José-María, Planelles-Catarino, Maria Victoria, Garcés-Sánchez, María, Ubeda, Isabel, Jubert–Rosich, Angels, Marès, Josep, Garcia-Corbeira, Pilar, Moris, Philippe, Teko, Maurice, Vanden Abeele, Carline, Gillard, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353319/ https://www.ncbi.nlm.nih.gov/pubmed/25652873 http://dx.doi.org/10.1111/irv.12295

Ejemplares similares

A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months
por: Carmona Martinez, Alfonso, et al.
Publicado: (2014)

Immunogenicity of Calvenza-03 EIV/EHV(®) Vaccine in Horses: Comparative In Vivo Study
por: Pavulraj, Selvaraj, et al.
Publicado: (2021)

An assessment of prime‐boost vaccination schedules with AS03(A)‐adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults
por: Gillard, Paul, et al.
Publicado: (2012)

Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies
por: Garcia-Sicilia, José, et al.
Publicado: (2015)

Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03(B) adjuvant: Results of a randomized phase I trial
por: Levy, Jack, et al.
Publicado: (2015)

PHASE 3 STUDY OF SAFETY AND IMMUNOGENICITY OF GBP510 VACCINE ADJUVANTED WITH AS03 IN ADULTS
por: Song, J.Y., et al.
Publicado: (2023)

Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities
por: Charland, Nathalie, et al.
Publicado: (2022)

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial
por: Leroux-Roels, Isabel, et al.
Publicado: (2022)

Immunogenicity Profile of a 3.75-μg Hemagglutinin Pandemic rH5N1 Split Virion AS03(A)-Adjuvanted Vaccine in Elderly Persons: A Randomized Trial
por: Heijmans, Stéphane, et al.
Publicado: (2011)

Safety and Immunogenicity of an AS03(B)-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized Study
por: Lin, Leyi, et al.
Publicado: (2020)

Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults
por: Madan, Anuradha, et al.
Publicado: (2016)

Immunogenicity and protective efficacy of GBP510/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques
por: Jacob-Dolan, Catherine, et al.
Publicado: (2023)

Immunogenicity of Viral Vaccines in the Italian Military
por: Ferlito, Claudia, et al.
Publicado: (2021)

Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials
por: Launay, Odile, et al.
Publicado: (2013)

Comparing the Immunogenicity of AS03-Adjuvanted 2009 Pandemic H1N1 Vaccine with Clinical Protection in Priority Risk Groups in England
por: Yung, Chee-Fu, et al.
Publicado: (2013)

Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant
por: Chen, Wilbur H., et al.
Publicado: (2014)

Flexibility of interval between vaccinations with AS03(A)-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18–60 and >60 years: a randomized trial
por: Duval, Xavier, et al.
Publicado: (2012)

AS03- and MF59-Adjuvanted Influenza Vaccines in Children
por: Wilkins, Amanda L., et al.
Publicado: (2017)

Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination
por: Strezova, Ana, et al.
Publicado: (2022)

Effectiveness of rotavirus vaccines, licensed but not funded, against rotavirus hospitalizations in the Valencia Region, Spain
por: Pérez-Vilar, Silvia, et al.
Publicado: (2015)

Immunogenicity and Efficacy of Vaccination in People Living with Human Immunodeficiency Virus
por: Tortellini, Eeva, et al.
Publicado: (2023)

Various Adjuvants Effect on Immunogenicity of Puumala Virus Vaccine
por: Kurashova, Svetlana S., et al.
Publicado: (2020)

CEC01-03 Safety of vaccines: a current perspective
por: Pallardy, M.
Publicado: (2022)

Secukinumab does not impair the immunogenic response to the influenza vaccine in patients
por: Richi, Patricia, et al.
Publicado: (2019)

Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study
por: de Bruyn, Guy, et al.
Publicado: (2023)

1139. Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Compared to a Meningococcal Reference Vaccine (MCV4-TT) in Healthy Adolescents
por: Díez-Domingo, Javier, et al.
Publicado: (2023)

H5N1 Influenza Vaccine Formulated with AS03(A) Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses
por: Moris, Philippe, et al.
Publicado: (2010)

The Differential Impact of Coadministered Vaccines, Geographic Region, Vaccine Product and Other Covariates on Pneumococcal Conjugate Vaccine Immunogenicity
por: Park, Daniel E., et al.
Publicado: (2014)

03. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered as a Booster Dose in Adults and Adolescents Vaccinated Against Meningococcal Disease 3 - 6 Years Earlier
por: Peterson, James, et al.
Publicado: (2021)

Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine
por: Hong, Eva, et al.
Publicado: (2016)

Immunogenicity of inactivated COVID-19 vaccines at different vaccination intervals
por: Li, Juan, et al.
Publicado: (2021)

Comparison of DNA vaccines with AS03 as an adjuvant and an mRNA vaccine against SARS-CoV-2
por: Neeli, Praveen, et al.
Publicado: (2023)

Short and Long-Term Safety of the 2009 AS03-Adjuvanted Pandemic Vaccine
por: De Serres, Gaston, et al.
Publicado: (2012)

P03-05. CD4 targeted vaccination in retroviral infection
por: Pike, R, et al.
Publicado: (2009)

Immunogenicity of infectious pathogens and vaccine antigens
por: Mahanty, Siddhartha, et al.
Publicado: (2015)

Methods for predicting vaccine immunogenicity and reactogenicity
por: Gonzalez-Dias, Patrícia, et al.
Publicado: (2019)

Micronutrients to Support Vaccine Immunogenicity and Efficacy
por: Calder, Philip C., et al.
Publicado: (2022)

Safety and immunogenicity of candidate vaccine M72/AS01(E) in adolescents in a TB endemic setting
por: Penn-Nicholson, Adam, et al.
Publicado: (2015)

Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults
por: Ikematsu, Hideyuki, et al.
Publicado: (2012)

Immunogenicity of Three Different Influenza Vaccines against Homologous and Heterologous Strains in Nursing Home Elderly Residents
por: Baldo, Vincenzo, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_lrij3182h0n890l3q4dg4bos09